Pollard R B, Onorato M
University of Texas Medical Branch, Galveston, USA.
Hosp Pract (1995). 1995 Aug;30 Suppl 1:32-40.
Viral resistance limits the value of drugs that act through competitive inhibition of HIV reverse transcriptase (RT). Thus, the emphasis of current research is on agents with other mechanisms. The possibilities include noncompetitive RT inhibitors, drugs against an entirely different enzyme--HIV proteinase, and measures to enhance immunity, either globally or against HIV specifically.
病毒耐药性限制了通过竞争性抑制HIV逆转录酶(RT)发挥作用的药物的价值。因此,当前研究的重点是具有其他作用机制的药物。这些可能性包括非竞争性RT抑制剂、针对一种完全不同的酶——HIV蛋白酶的药物,以及全面增强免疫力或特异性增强针对HIV免疫力的措施。